Page last updated: 2024-08-22

zalcitabine and saquinavir

zalcitabine has been researched along with saquinavir in 71 studies

Research

Studies (71)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	56 (78.87)	18.2507
2000's	8 (11.27)	29.6817
2010's	6 (8.45)	24.3611
2020's	1 (1.41)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Chou, TC; Hirsch, MS; Johnson, VA; Merrill, DP	1
Burke, A; Martin, JA; Mobberley, MA; Redshaw, S; Ryder, TA; Tyms, AS	1
Nelson, H	1
Connell, EV; Hsu, MC; Richman, DD	1
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS	1
Barry, DW; Pennington, KN; Rooney, J; St Clair, MH	1
Baruch, A; Bassett, RL; Collier, AC; Coombs, RW; Corey, L; Facey, K; Friedman, HM; Hooper, C; Jones, M; McAuliffe, VJ; Merigan, TC; Reichman, RC; Schoenfeld, DA; Timpone, J; Whitacre, C	1
Borkow, G; Castriota, G; Drosopoulos, WC; Gu, Z; Hsu, M; Islam, S; Manne, J; Parniak, M; Prasad, VR; Salomon, H; Song, Q; Wainberg, MA	1
Bender, AR; Duncan, IB; Kreuter, J; Rübsamen-Waigmann, H; von Briesen, H	1
Albrecht, H; Fenner, T; Greten, H; Lichtenberg, G; Stellbrink, HJ; Thiele, HG; van Lunzen, J; Zöller, B	1
Hoof, T	1
Augenbraun, M; Minkoff, H	1
Hirschel, B; Rutschmann, O	1
Heins, JR	1
Bürgisser, P; Meylan, PR; Pagani, JL; Spertini, F; Weyrich-Suter, C	1
Costello, CE; Nelson, MR; Walsh, JC	1
Collins, DO; Sakamoto, A	1
Blaschke, TF; Collier, AC; Gries, JM; Kastrissios, H; Park, K; Sheiner, LB; Squires, K; Vanhove, GF; Verotta, D	1
Blaschke, TF; Collier, AC; Coombs, R; Gries, JM; Sheiner, LB; Vanhove, GF; Verotta, D	1
Becagli, P; Berto, V; Font, M; Martini, N; Messori, A; Tosolini, F; Trippoli, S; Venturini, F	1
Back, DJ; Barry, MG; Hoggard, PG; Manion, V	1
Blanchard, G; Blum, L; Calvo, F; Danne, O; Lebbé, C; Morel, P; Pellet, C; Vérola, O	1
Cammack, N; Dissanayeke, SR; Duncan, IB; Gilbert, SM; Moffatt, AR; Race, E; Rose, JS; Sheldon, JG; Sitbon, G	1
Bachmeyer, C; Blum, L	1
Saag, MS; Schooley, RT	1
Boirivant, M; Camponeschi, B; Di Genova, G; Quaranta, MG; Viora, M	1
González-Lahoz, J; Jiménez-Nacher, I; Moreno Celda, V; Rodríguez-Rosado Martínez-Echevarría, R; Soriano Vázquez, V; Valencia Ortega, E	1
Collier, AC; Coombs, RW; Efron, B; Lawrence, J; Merigan, TC; Schapiro, JM; Speck, R; Winters, MA	1
Gitterman, SR; Pratt, RD; Struble, KA	1
Barker, C; Moyle, G; Revicki, DA; Stellbrink, HJ	1
Temesgen, Z; Wright, AJ	1
Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S	1
Avrămescu, C; Balasoiu, M; Radu, E; Turculeanu, A; Voiculescu, C	1
Collier, AC; Haubrich, R; Revicki, DA; Swartz, C; Wu, AW	1
Gazzard, BG; Moyle, GJ	1
Albrecht, H; Hufert, FT; Lauer, J; Racz, P; Schneider, C; Stellbrink, HJ; Tenner-Racz, K; van Lunzen, J	1
Berger, AR; Eng, KT; Liu, ES; Silverman, MS	1
Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M	1
Bossi, P; Calvez, V; Delaugerre, C; Delfraissy, JF; Diquet, B; Do, B; Dohin, E; Katlama, C; Legrand, M; Mouroux, M; Peytavin, G; Trylesinski, A; Yvon-Groussin, A	1
Conant, M	1
Vella, S	1
Levin, J	1
Baker, R	2
Chang, HE	1
Smart, T	2
Alcorn, K	1
MacDougall, DS	1
Aquilina, C; Calvez, V; Delfraissy, JF; Dohin, E; Goehrs, JM; Katlama, C; Lacoste, D; Lantz, O; Montestruc, F; Mouroux, M; Pellegrin, JL; Pialoux, G; Raffi, F; Raguin, G; Trylesinski, A; Vittecoq, D	1
Macher, A; Paul, SM; Thomas, D	1

Reviews

9 review(s) available for zalcitabine and saquinavir

Article	Year
Membrane transporters in drug development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3 Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs	2010
Antiretroviral therapy for pregnant women. American journal of obstetrics and gynecology, 1997, Volume: 176, Issue:2 Topics: Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Zalcitabine; Zidovudine	1997
Antiretroviral therapy: a guide to the most important trials. Schweizerische medizinische Wochenschrift, 1997, Mar-15, Volume: 127, Issue:11 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine	1997
[Antiretroviral treatment in human immunodeficiency virus infection]. Annales de dermatologie et de venereologie, 1997, Volume: 124, Issue:9 Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine	1997
Antiretroviral chemotherapy. Current clinical topics in infectious diseases, 1998, Volume: 18 Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine	1998
Toxicity of antiretroviral agents. The American journal of medicine, 1997, May-19, Volume: 102, Issue:5B Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine	1997
Antiretrovirals. Mayo Clinic proceedings, 1999, Volume: 74, Issue:12 Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine	1999
Finding a role for zalcitabine in the HAART era. Antiviral therapy, 1998, Volume: 3, Issue:3 Topics: Anti-HIV Agents; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Saquinavir; Zalcitabine; Zidovudine	1998
Contraindicated antiretroviral drug combinations. New Jersey medicine : the journal of the Medical Society of New Jersey, 2003, Volume: 100, Issue:9 Suppl Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine	2003

Trials

13 trial(s) available for zalcitabine and saquinavir

Article	Year
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. The New England journal of medicine, 1996, Apr-18, Volume: 334, Issue:16 Topics: Adult; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Male; Quinolines; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine	1996
Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment. AIDS (London, England), 1996, Volume: 10, Issue:8 Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Seropositivity; HIV-1; Humans; Kinetics; Male; RNA, Viral; Saquinavir; Viral Load; Zalcitabine; Zidovudine	1996
Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration. The Journal of infectious diseases, 1997, Volume: 175, Issue:5 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biopsy, Needle; CD4 Lymphocyte Count; CD4-CD8 Ratio; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; HIV-1; Humans; Lymph Nodes; Polymerase Chain Reaction; Regression Analysis; RNA Splicing; RNA, Viral; Saquinavir; Single-Blind Method; Viremia; Zalcitabine; Zidovudine	1997
Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:11 Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Saquinavir; Zalcitabine; Zidovudine	1997
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:11 Topics: Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Saquinavir; Zalcitabine; Zidovudine	1997
Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS (London, England), 1998, Aug-20, Volume: 12, Issue:12 Topics: Amino Acid Sequence; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Phenotype; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine	1998
[Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus]. Revista clinica espanola, 1998, Volume: 198, Issue:9 Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Saquinavir; Zalcitabine; Zidovudine	1998
Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. The Journal of infectious diseases, 1999, Volume: 179, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Codon; Cohort Studies; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease; HIV-1; Humans; Mutation; RNA, Viral; Saquinavir; Time Factors; Zalcitabine; Zidovudine	1999
Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. AIDS (London, England), 1999, May-07, Volume: 13, Issue:7 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Quality of Life; Reverse Transcriptase Inhibitors; Saquinavir; Treatment Outcome; Zalcitabine; Zidovudine	1999
Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antiviral therapy, 1999, Volume: 4, Issue:1 Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Quality of Life; Saquinavir; Zalcitabine	1999
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. The Journal of infectious diseases, 2000, Volume: 181, Issue:5 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine	2000
Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance. Journal of clinical microbiology, 2000, Volume: 38, Issue:7 Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Zalcitabine	2000
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine. HIV medicine, 2001, Volume: 2, Issue:1 Topics: Adult; Anti-HIV Agents; Capsules; Drug Administration Schedule; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Count; Male; Middle Aged; Pilot Projects; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine	2001

Other Studies

49 other study(ies) available for zalcitabine and saquinavir

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. The Journal of infectious diseases, 1992, Volume: 166, Issue:5 Topics: Cells, Cultured; Drug Interactions; Drug Resistance, Microbial; HIV Protease Inhibitors; HIV-1; Humans; Interferon Type I; Isoquinolines; Kinetics; Monocytes; Quinolines; Recombinant Proteins; Saquinavir; Virus Replication; Zalcitabine; Zidovudine	1992
The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells. Biochemical and biophysical research communications, 1991, Apr-15, Volume: 176, Issue:1 Topics: Animals; Antiviral Agents; Cell Line; Didanosine; HIV Protease; HIV Protease Inhibitors; Humans; Microscopy, Electron; Saquinavir; Simian Immunodeficiency Virus; Zalcitabine	1991
FDA advised to license three anti-HIV agents. Lancet (London, England), 1995, Nov-18, Volume: 346, Issue:8986 Topics: Adult; Antiviral Agents; Child; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine	1995
Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:2 Topics: Antiviral Agents; Benzodiazepines; Didanosine; Drug Synergism; Gene Products, tat; HeLa Cells; HIV; HIV Protease Inhibitors; Humans; Isoquinolines; Nevirapine; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; tat Gene Products, Human Immunodeficiency Virus; Zalcitabine; Zidovudine	1994
The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Antiviral research, 1995, Volume: 26, Issue:2 Topics: Antiviral Agents; Cells, Cultured; Cytotoxicity Tests, Immunologic; Didanosine; Drug Interactions; HIV Reverse Transcriptase; HIV-1; Humans; Indolizines; Isoquinolines; Leukocytes, Mononuclear; Molecular Structure; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Uracil; Zalcitabine; Zidovudine	1995
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol. Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1995, Volume: 10 Suppl 2 Topics: Antiviral Agents; Cell Line, Transformed; Cytopathogenic Effect, Viral; Didanosine; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nevirapine; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Saquinavir; Virus Replication; Zalcitabine; Zidovudine	1995
New drugs for HIV infection. The Medical letter on drugs and therapeutics, 1996, Apr-12, Volume: 38, Issue:972 Topics: Antiviral Agents; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Zalcitabine	1996
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (New York, N.Y.), 1996, Mar-01, Volume: 271, Issue:5253 Topics: Antiviral Agents; Base Composition; Base Sequence; Deoxyribonucleotides; Drug Resistance, Microbial; HIV Antibodies; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Isoquinolines; Lamivudine; Molecular Sequence Data; Mutation; Neutralization Tests; Quinolines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Saquinavir; Virus Replication; Zalcitabine	1996
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:6 Topics: Antiviral Agents; Cells, Cultured; Cyanoacrylates; Drug Carriers; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Macrophages; Monocytes; Particle Size; Saquinavir; Zalcitabine	1996
[The combination of saquinavir and ddC ensures longer survival]. Deutsche medizinische Wochenschrift (1946), 1996, Sep-13, Volume: 121, Issue:37 Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Saquinavir; Zalcitabine	1996
[HIV: to administer protease inhibitors early]. Deutsche medizinische Wochenschrift (1946), 1996, Dec-06, Volume: 121, Issue:49 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Time Factors; Zalcitabine; Zidovudine	1996
Treatment options for human immunodeficiency virus. South Dakota journal of medicine, 1996, Volume: 49, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine	1996
Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy. AIDS (London, England), 1997, Volume: 11, Issue:3 Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Saquinavir; Thrombocytopenia; Zalcitabine; Zidovudine	1997
Cure or control of HIV/AIDS? Medical hypotheses, 1997, Volume: 48, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine	1997
Drugs for HIV infection. The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015 Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine	1997
Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci. The Annals of pharmacotherapy, 1997, Volume: 31, Issue:12 Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; HIV Infections; Humans; Research Design; Saquinavir; Survival Analysis; Zalcitabine; Zidovudine	1997
Effect of protease inhibitors on nucleoside analogue phosphorylation in vitro. British journal of clinical pharmacology, 1998, Volume: 45, Issue:2 Topics: Anti-HIV Agents; Cell Count; Cell Survival; Didanosine; Drug Interactions; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Nucleosides; Phosphorylation; Protease Inhibitors; Ritonavir; Saquinavir; Stavudine; Trypan Blue; Tumor Cells, Cultured; Zalcitabine; Zidovudine	1998
Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS (London, England), 1998, May-07, Volume: 12, Issue:7 Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; Herpesvirus 8, Human; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sarcoma, Kaposi; Stavudine; Treatment Outcome; Viral Load; Viremia; Zalcitabine; Zidovudine	1998
Lack of immunotoxicity of saquinavir (Ro 31-8959) used alone or in double or triple combination with AZT and ddC. Journal of clinical immunology, 1998, Volume: 18, Issue:5 Topics: Antiviral Agents; Cytotoxicity, Immunologic; Cytotoxins; Drug Combinations; Humans; Intestines; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Phytohemagglutinins; RNA, Messenger; Saquinavir; Zalcitabine; Zidovudine	1998
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS research and human retroviruses, 1999, Dec-10, Volume: 15, Issue:18 Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine	1999
Current laboratory assays and in vitro intracellular Th1 and Th2 cytokine synthesis in monitoring antiretroviral therapy of pediatric HIV infection. FEMS immunology and medical microbiology, 2000, Volume: 27, Issue:1 Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Saquinavir; Th1 Cells; Th2 Cells; Viral Load; Zalcitabine; Zidovudine	2000
Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2. Antiviral therapy, 1998, Volume: 3, Issue:4 Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Interleukin-2; Kinetics; Lymphoid Tissue; Male; Middle Aged; RNA, Viral; Saquinavir; Viremia; Zalcitabine; Zidovudine	1998
Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors. Archives of ophthalmology (Chicago, Ill. : 1960), 2000, Volume: 118, Issue:3 Topics: Acquired Immunodeficiency Syndrome; Adult; Cholesterol; Delavirdine; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Retinal Diseases; Retinal Vessels; Ritonavir; Saquinavir; Triglycerides; Viral Load; Zalcitabine	2000
Saquinavir combination results released. AIDS patient care and STDs, 1996, Volume: 10, Issue:4 Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Organic Chemicals; Saquinavir; Survival Analysis; Zalcitabine	1996
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James. AIDS treatment news, 1995, Aug-04, Issue:no 228 Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine	1995
Roche submits NDA for Invirase. Journal of the International Association of Physicians in AIDS Care, 1995, Volume: 1, Issue:8 Topics: Clinical Trials as Topic; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Investigational New Drug Application; Isoquinolines; Quinolines; Saquinavir; United States Food and Drug Administration; Zalcitabine; Zidovudine	1995
Update on HIV protease inhibitors. AIDS clinical care, 1995, Volume: 7, Issue:10 Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Design; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Phosphorylation; Pyridines; Quinolines; Ritonavir; Saquinavir; Substrate Specificity; Thiazoles; Valine; Zalcitabine; Zidovudine	1995
Protease inhibitors and prevention of cross resistance. AIDS treatment news, 1995, Oct-06, Issue:no 232 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine	1995
3TC and saquinavir: we need them now. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995 Topics: Antiviral Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine	1995
Conference looks at HIV drug resistance. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9 Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine	1995
FDA triple header. Food and Drug Administration. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:11 Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Mutation; Quinolines; Salvage Therapy; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine	1995
A kinder, gentler ddC... for $7,200 a year. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:12 Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Zalcitabine	1995
FDA approves 3TC and saquinavir. Food and Drug Administration. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995 Topics: Antiviral Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine	1995
FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration. AIDS treatment news, 1995, Oct-20, Issue:no 233 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine	1995
Potent new AIDS drugs underscore promise of combination therapy. AIDS alert, 1996, Volume: 11, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine	1996
Europe out of step with the US. Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:1 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Didanosine; Drug Costs; Europe; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Ritonavir; Saquinavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine	1996
Saquinavir: combination shows survival benefit; new formulation trial recruiting. AIDS treatment news, 1996, May-03, Issue:no 246 Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine	1996
Ritonavir: first to prolong survival. Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:4 Topics: Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Ritonavir; Saquinavir; Thiazoles; Valine; Zalcitabine; Zidovudine	1996
Saquinavir prolongs survival and slows disease progression. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1996 Topics: CD4 Lymphocyte Count; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine	1996
Saquinavir plus ddC reduces deaths by more than two-thirds. Journal of the International Association of Physicians in AIDS Care, 1996, Volume: 2, Issue:6 Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Isoquinolines; Quinolines; Saquinavir; Survival Rate; Zalcitabine	1996
Nipping HIV in the bud. GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:8 Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine	1996